Acceleron will produce ACE-536 for the Phase 1 and Phase 2 scientific trials and Celgene will have responsibility for the produce of Phase 3 and commercial supplies. Acceleron will pay a talk about of the development expenditures through the end of 2012 and Celgene will be responsible for development costs thereafter. Acceleron is eligible to receive advancement, regulatory and commercial milestones as high as $217 million for the ACE-536 program. The ongoing companies will co-promote the merchandise in North America. Acceleron shall receive tiered double-digit royalties on worldwide net sales.. Acceleron, Celgene enter advancement collaboration for ACE-536 protein therapeutic to treat anemia Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for tumor and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint advancement and commercialization agreement for ACE-536 for the treating anemia.The scholarly study is section of the Carotid Revascularization Endarterectomy vs. Stenting Trial . It was presented in summary form at the International Stroke Conference in San Antonio, Texas, Feb. 26. Stroke, the third-leading reason behind death in the country, is due to an interruption in blood circulation to the mind by a bleeding or clot. The carotid arteries on each side of the neck are the major source of blood flow to the brain. The buildup of cholesterol in the wall of the carotid artery, called atherosclerotic plaque, can be one reason behind stroke. CREST compares endarteroctomy, a surgical procedure to clear blocked blood flow and prevent stroke, with carotid stenting, a more recent procedure that involves threading a stent and growing a small protective gadget in the artery to widen the blocked area and capture dislodged plaque.